After H.C. Wainwright and Chardan Capital gave Dicerna Pharma (NASDAQ: DRNA) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Mayank Mamtani reiterated a Buy rating on Dicerna Pharma today and set a price target of $30.00. The company’s shares closed last Monday at $20.58.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 14.4% and a 50.5% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $33.60 average price target, which is a 58.4% upside from current levels. In a report issued on August 7, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $34.03 million and GAAP net loss of $22.49 million. In comparison, last year the company earned revenue of $3.11 million and had a GAAP net loss of $26.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
